908 Devices Inc. (NASDAQ:MASS – Get Rating) – William Blair increased their FY2022 earnings per share (EPS) estimates for 908 Devices in a research report issued on Tuesday, January 17th. William Blair analyst M. Larew now anticipates that the company will post earnings of ($0.95) per share for the year, up from their previous forecast of ($0.98). The consensus estimate for 908 Devices’ current full-year earnings is ($0.99) per share. William Blair also issued estimates for 908 Devices’ Q4 2022 earnings at ($0.20) EPS, Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at ($0.30) EPS, Q3 2023 earnings at ($0.23) EPS, Q4 2023 earnings at ($0.19) EPS and FY2023 earnings at ($1.00) EPS.
Separately, SVB Leerink lowered their target price on 908 Devices from $25.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, January 6th.
908 Devices Trading Up 1.0 %
908 Devices (NASDAQ:MASS – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. 908 Devices had a negative return on equity of 13.30% and a negative net margin of 53.36%. The company had revenue of $15.80 million during the quarter, compared to analyst estimates of $15.76 million.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. UBS Group AG increased its holdings in 908 Devices by 171.0% during the 3rd quarter. UBS Group AG now owns 2,439 shares of the company’s stock valued at $40,000 after purchasing an additional 1,539 shares during the period. Amalgamated Bank purchased a new position in shares of 908 Devices during the 1st quarter worth approximately $58,000. US Bancorp DE purchased a new position in shares of 908 Devices during the 3rd quarter worth approximately $66,000. Tower Research Capital LLC TRC grew its holdings in shares of 908 Devices by 480.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,677 shares of the company’s stock worth $110,000 after acquiring an additional 5,527 shares during the period. Finally, Quantbot Technologies LP grew its holdings in shares of 908 Devices by 960.8% during the 1st quarter. Quantbot Technologies LP now owns 6,365 shares of the company’s stock worth $120,000 after acquiring an additional 5,765 shares during the period. Hedge funds and other institutional investors own 80.53% of the company’s stock.
908 Devices Company Profile
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
- Get a free copy of the StockNews.com research report on 908 Devices (MASS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.